RD07 / Nanjing Bioheng Biotech - LARVOL DELTA

Efficacy and immunomodulatory effect of Claudin18.2-specific IL-7/XCL1 armored CAR-T cells in digestive tract cancer: preclinical and clinical analysis. (PubMed, Signal Transduct Target Ther) - "Taken together, present data demonstrate the therapeutic efficacy and safety of RD07 in our study and highlight its ability to both exert antitumor effects and remodel the TME. These findings support RD07 as an innovative CAR-T cell therapy for DTC."

IO biomarker • Journal • Preclinical • Oncology • Solid Tumor • CLDN18 • IL7

RD07 in Patients With Advanced Claudin18.2+ Solid Tumors (ChiCTR) - P=N/A | N=18 | Completed | Sponsor: The First Affiliated Hospital of Zhengzhou University; The First Affiliated Hospital of Zhengzhou University | Not yet recruiting ➔ Completed

Trial completion • Gastric Cancer • Oncology • Solid Tumor • CLDN18

Efficacy and immunomodulatory of Claudin18.2-specific IL-7/XCL1 armored CAR-T cells in digestive tract cancers (SITC 2024) - P=N/A | "All of the patients underwent lymphodepletion consisting of cyclophosphamide, fludarabine or nab-paclitaxel before RD07 infusion at a dose of 0.1–2×107 cells/kg body weight. Consent Written informed consent was obtained from the patient for publication of this abstract and any accompanying images. A copy of the written consent is available for review by the Editor of this journal.View this table:View inline View popup Download powerpoint Abstract 1458 Table 1 Aggregate baseline characteristics of all patientsDownload figure Open in new tab Download powerpoint Abstract 1458 Figure 1 Waterfall plot and Spider plot for each patient"

CAR T-Cell Therapy • Clinical • Immunomodulating • IO biomarker • Late-breaking abstract • Gastrointestinal Cancer • Hematological Malignancies • Oncology • CLDN18 • IL7